Skip to main content
. 2022 Feb 10;12:809754. doi: 10.3389/fonc.2022.809754

Figure 4.

Figure 4

Overcoming the barriers of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), tumor microenvironment (MVT), and complex process through in-vivo CAR-T cell induced by nanomedicines composed of nano-carrier loaded with the CAR structure or a gene-editing tool.